contrafect产品代理

ContraFect   is a clinical-stage biotechnology company focused on discovering and   developing biologic therapies for life-threatening, drug-resistant infectious   diseases, particularly those treated in hospital settings. An estimated   700,000 deaths worldwide each year are attributed to antimicrobial-resistant   infections. We intend to address life threatening infections using our   therapeutic product candidates from our platform of direct lytic agents   (DLAs), which include lysins and amurin peptides. We believe DLAs provide the   opportunity to make meaningful improvements to clinical outcomes and to   change the treatment paradigm for patients infected with antibiotic-resistant   bacteria. Our initial product candidates are new agents to treat lethal,   resistant infections such as methicillin-resistant Staph aureus (MRSA) and   Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas   aeruginosa.

Our   therapeutic product candidates are direct lytic agents (DLAs) that represent   a new, potential paradigm shift in the approach to treating bacterial   infections, including those caused by drug-resistant pathogens.  Our focus is on achieving superior clinical   outcomes for patients over current standard of care.

Drug resistance occurs when microbes such as bacteria and viruses change in ways that allow them to grow despite antibiotic and antiviral treatment. Overuse of antibiotics has contributed to dramatic increases in the prevalence of drug resistant bacteria, such as MRSA, which require longer and more expensive courses of treatment and are associated with substantial morbidity and mortality.